22 articles for P Shah
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
38
Discovery of potent inhibitors of the lysophospholipase autotaxin.
Babraham Research Campus
31
Lead optimization of isocytosine-derived xanthine oxidase inhibitors.
Piramal Healthcare
27
The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist.
Medicines Research Centre
19
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Piramal Healthcare
12
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
Piramal Healthcare
4
Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151).
Gsk
5
The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate.
Glaxowellcome Medicines Research Centre
12
Intracellular inhibition of human neutrophil elastase by orally active pyrrolidine-trans-lactams.
Glaxowellcome Medicines Research Centre
2
Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent.
Central Drug Research Institute (Csir)
11
Synthesis of novel 3-amino and 29-hydroxamic acid derivatives of glycyrrhetinic acid as selective 11ß-hydroxysteroid dehydrogenase 2 inhibitors.
University of Natural Resources and Applied Life Sciences
23
CoMFA analysis of dual/multiple PPAR activators.
National Institute of Pharmaceutical Education and Research
37
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia.
National Center for Advancing Translational Sciences
30
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia.
National Center for Advancing Translational Sciences
1
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
University of Kansas
89
Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties.
National Institutes of Health
39
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
National Center For Advancing Translational Sciences
25
The identification of novel orally active mGluR5 antagonist GSK2210875.
Medicines Research Centre
7
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
The University of Texas M.D. Anderson Cancer Center
55
Discovery and lead identification of quinazoline-based BRD4 inhibitors.
National Institutes of Health
107
Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity.
National Center For Advancing Translational Sciences
